The effectiveness of UVB (311 nm emission) therapy and cyclosporine treatment in the patients with poor responsiveness to TNF-a blockers

Dmitry Nikolaevich Serov; L. S Kruglova; E. N Ponich

doi:10.18821/1681-3456-2016-15-6-310-314

Russian Journal of Physiotherapy, Balneology and Rehabilitation ›› 2016, Vol. 15 ›› Issue (6) : 310 -314. DOI: 10.18821/1681-3456-2016-15-6-310-314

Articles

research-article

The effectiveness of UVB (311 nm emission) therapy and cyclosporine treatment in the patients with poor responsiveness to TNF-a blockers

Author information +

History +

PDF

Abstract

The authors present data concerning the effectiveness of the application of UVB (311 nm emission) therapy and the treatment using low doses of cyclosporine in the patients receiving therapy with TNF-alpha blockers that resulted in the 50% reduction of the Psoriasis Area and Severity Index (PASI 50). The study has demonstrated that the introduction of narrow-band phototherapy into the combined treatment can make it possible to reach the PASI values of 75 and even 100%. Monitoring of the safety of the application of the combined approach has revealed the absence of early adverse reactions within 1 year after the treatment.

Keywords

severe psoriasis / narrow-band UVB (311 nm emission) phototherapy / cyclosporine / TNF-a blockers / PASI 75 / PASI 100

Cite this article

Download citation ▾

Dmitry Nikolaevich Serov, L. S Kruglova, E. N Ponich. The effectiveness of UVB (311 nm emission) therapy and cyclosporine treatment in the patients with poor responsiveness to TNF-a blockers. Russian Journal of Physiotherapy, Balneology and Rehabilitation, 2016, 15(6): 310-314 DOI:10.18821/1681-3456-2016-15-6-310-314

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Потекаев Н.Н., Круглова Л.С. Псориатическая болезнь. М.: МДВ. 2014.

[2]	Nast A., Kopp I., Augustin M. et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch. Dermatol. Res. 2007; 299(3): 111-38.

[3]	Conway, Pete-Currie, Craig J. Descriptive epidemiology of hospitalisation for psoriasis. Curr. Med. Res. Opin. 2008; 24: 12: ProQuest Centralpg. 3487.

[4]	Sabat R., Philipp S., Höflich C. et al. Immunopathogenesis of psoriasis. Exp. Dermatol. 2007; 16(10): 779-98.

[5]	Cauza E., Cauza K., Hanusch-Enserer U., Etemad M., Dunky A., Kostner K. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien. Klin. Wschr. 2002; 114: 1004-7.

[6]	Zhu T.Y., Li E.K., Tam L.S. Cardiovascular risk in patients with psoriatic arthritis. Int. J. Rheumatol. 2012: 714321.

[7]	Raychaudhuri S.P. Comorbidities of psoriatic arthritis - metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J. Rheumatol. 2012; 39: 437-40.

[8]	Ma C., Harskamp C.T., Armstrong E.J. et al. The association between psoriasis and dyslipidaemia: a systematic review. Br. J. Dermatol. 2013; 168: 468-95.

[9]	Cohen A.D., Dreiher J., Shapiro Y. et al. Psoriasis and diabetes: a population based crosssectional study. J. Eur. Acad. Dermatol. Venereol. 2008; 22: 585-9.

[10]	Gelfand J.M., Neimann A.L., Shin D.B. et al. Risk of myocardial infarction in patients with psoriasis. J.A.M.A. 2006; 296: 1735-41.

[11]	Xu T., Zhang Y.H. Association of psoriasis with stroke and myocardial infarction: a metaanalysis of cohort studies. Br. J. Dermatol. 2012; 167: 1345-50.

[12]	Cohen A.D., Weitzman D. Psoriasis and hypertension: a case-control study. Acta Derm. Venereol. 2010; 90: 23-6.

[13]	Neimann A.L., Shin D.B., Wang X. et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 2006; 55: 829-35.